About: New Strategies in Drug Discovery

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: New Strategies in Drug Discovery Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	New Strategies in Drug Discovery
Creator	Johnson, Anthony Elliott, John Ohlstein, Eliot Romanic, Anne
source	PMC
abstract	Gene identification followed by determination of the expression of genes in a given disease and understanding of the function of the gene products is central to the drug discovery process. The ability to associate a specific gene with a disease can be attributed primarily to the extraordinary progress that has been made in the areas of gene sequencing and information technologies. Selection and validation of novel molecular targets have become of great importance in light of the abundance of new potential therapeutic drug targets that have emerged from human gene sequencing. In response to this revolution within the pharmaceutical industry, the development of high-throughput methods in both biology and chemistry has been necessitated. Further, the successful translation of basic scientific discoveries into clinical experimental medicine and novel therapeutics is an increasing challenge. As such, a new paradigm for drug discovery has emerged. This process involves the integration of clinical, genetic, genomic, and molecular phenotype data partnered with cheminformatics. Central to this process, the data generated are managed, collated, and interpreted with the use of informatics. This review addresses the use of new technologies that have arisen to deal with this new paradigm.
has issue date	2006-01-01(xsd:dateTime)
bibo:doi	10.1385/1-59259-964-8:1
bibo:pmid	16671397
has license	no-cc
sha1sum (hex)	977fa0ab0a932301ddf0f47525505b08b4f0798a
schema:url	https://doi.org/10.1385/1-59259-964-8:1
resource representing a document's title	New Strategies in Drug Discovery
has PubMed Central identifier	PMC7120019
has PubMed identifier	16671397
schema:publication	Bioinformatics and Drug Discovery
resource representing a document's body	covid:977fa0ab0a932301ddf0f47525505b08b4f0798a#body_text
is schema:about of	named entity 'specific' named entity 'cheminformatics' named entity 'integration' named entity 'paradigm' named entity 'UNDERSTANDING' named entity 'DEAL' named entity 'PROCESS' named entity 'MOLECULAR' named entity 'GENOMIC' named entity 'DISEASE' named entity 'expression' named entity 'Gene' named entity 'potential' named entity 'molecular' named entity 'therapeutics' named entity 'determination' named entity 'validation' named entity 'attributed' named entity 'therapeutic drug targets' named entity 'drug discovery' named entity 'high-throughput methods' named entity 'cheminformatics' named entity 'drug discovery' named entity 'paradigm' named entity 'gene products' named entity 'Drug Discovery' named entity 'organ culture' named entity 'adsorption' named entity 'toxicity' named entity 'pharmacogenomic' named entity 'ion exchange' named entity 'toxicity' named entity 'carcinogenicity' named entity 'coronary artery disease' named entity 'Human Genome Project' named entity 'drug discovery' named entity 'Metabolic' named entity 'inflammation' named entity 'p38' named entity 'Abacavir' named entity 'gene' named entity 'small molecules' named entity 'laser' named entity 'HTS' named entity 'toxicogenomics' named entity 'urine' named entity 'enzyme-linked immunosorbent assay' named entity 'genes are expressed' named entity 'vasoconstriction' named entity 'magnetic resonance imaging' named entity 'genotype' named entity 'genome' named entity 'alternative splicing' named entity 'phosphorylation' named entity 'high-throughput methods' named entity 'phenotype' named entity 'transcription factors' named entity 'hydrophilic' named entity 'c-Jun' named entity 'drug discovery' named entity 'dietary fats' named entity 'paradigm' named entity 'drug therapy' named entity 'gene expression' named entity 'potassium channel' named entity 'gene sequencing' named entity 'expression of genes' named entity 'protein' named entity 'human DNA' named entity 'peptide' named entity 'proteomic analysis' named entity 'organ culture' named entity 'polyacrylamide gels' named entity 'Pharmacogenomics' named entity 'neuropeptide' named entity 'IL-8' named entity 'lateral hypothalamic' named entity 'adverse event'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software